May 2-4, 2018 Rome, Italy

Importance of Pharmacogenomics in the Success of Drug Therapy

David W Hein

University of Louisville, USA

Individual patient differences in drug responsiveness are well recognized by health care professionals. Understanding the basis for these differences is of major clinical and economic importance because of the high frequency of both therapeutic failure and adverse reactions to drugs. Patients may receive inadequate or suboptimal benefit and/or suffer adverse effects from drug treatment. In this presentation, we highlight pharmacogenetic/pharmacogenomic principles and provide illustrative examples where these principles can be applied to optimize therapeutic benefit and minimize adverse effects.

Biography:

Dr. Hein serves as Peter K. Knoefel Endowed Chair of Pharmacology, Professor and Chairman of the Department of Pharmacology & Toxicology, and Distinguished University Scholar at the University of Louisville (USA). His research program includes studies of the molecular epidemiology of cancer susceptibility, pharmacogenetics, genomics, personalized medicine, and functional genomics. He has coauthored over 240 peer-reviewed journal articles and book chapters, 75 published gene sequences, and over 600 abstracts. The publications have over 13, 000 citations with an h-index 58. He has served as principal investigator/co-investigator/mentor on over 75 research grants and contracts totaling over \$50 million dollars.